Probiotic peanut oral immunotherapy is associated with long‐term persistence of 8‐week sustained unresponsiveness and long‐lasting quality‐of‐life improvement
Paxton Loke(Royal Children's Hospital), Mimi L.K. Tang(Royal Children's Hospital), Kaushala S. Jayawardana(Murdoch Children's Research Institute), Agnes Sze Yin Leung(Chinese University of Hong Kong), Melanie Lloyd(Royal Children's Hospital), Marnie Robinson(Royal Children's Hospital), Sarah Ashley(Royal Children's Hospital), Sigrid Pitkin(Murdoch Children's Research Institute), Dean Tey(Royal Children's Hospital), Ee Lyn Su(Royal Children's Hospital), Audrey Dunn Galvin(University College Cork), Adriana Chebar Lozinsky(Murdoch Children's Research Institute), Christine Axelrad(Murdoch Children's Research Institute), Kuang‐Chih Hsiao(University of Melbourne)
Cited by 11
Related Papers
Administration of a probiotic with peanut oral immunotherapy: A randomized trial
|Journal of Allergy and Clinical Immunology|2015|436
The epidemiology of anaphylaxis in Europe: a systematic review
|Allergy|2013|406
Food allergy across the globe
|Journal of Allergy and Clinical Immunology|2021|296
Probiotics for treating eczema
|Cochrane Database of Systematic Reviews|2008|230
Food protein–induced enterocolitis syndrome in Australia: A population-based study, 2012-2014
|Journal of Allergy and Clinical Immunology|2017|200